Effekten af GCP-direktivet pa forskerinitierede kliniske laegemiddelforsog--sekundaerpublikation

L. Berendt, C. Hakansson, K.F. Bach, K. Dalhoff, P.B. Andreasen, L.G. Petersen, E. Andersen, H.E. Poulsen

    Abstract

    Since 2004, adherence to Good Clinical Practice has been mandatory for all clinical drug trials. This was new to the investigator-initiated trials. Our study showed no association between the implementation of the Directive and investigator or industry-initiated trials. However, a steady decline was observed over the entire period. Presumably, the introduction of GCP did not entail a decline because of the presence of GCP units at university hospitals. Thus, researchers can conduct clinical drug trials under the same regulations as drug companies
    Udgivelsesdato: 2008/8/11
    OriginalsprogDansk
    TidsskriftUgeskrift for læger
    Vol/bind170
    Udgave nummer33
    Sider (fra-til)2437-2439
    Antal sider2
    ISSN0041-5782
    StatusUdgivet - 2008

    Citationsformater